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Dear Editor,
I
n  their  meta-analysis  of  the  efficacy  of 
peginterferon alfa-2a (PEG-IFN-α2a) or alfa-
2b (PEG-IFN-α2b) and ribavirin for the treatment of 
hepatitis C virus (HCV), Alavian et al. (1), analyzing 
pooled data from 7 studies, conclude that PEG-IFN-
α2a (with similar safety) is more effective than PEG-
IFN-α2b.  While  PEG-IFN  alfa-2b  with  ribavirin 
is generally considered as the treatment of choice 
for chronic HCV infection (2), the findings of this 
study sound at first like good news, especially since 
PEG-IFN alfa-2a is more cost-effective than PEG-
IFN alfa-2b (3); but we suggest that the findings of 
this study should be open to a more conservative 
interpretation. 
Because of the nature of meta-analysis, we cannot 
expect in the current article to consider all the major 
factors  that  may  interfere  or  otherwise  affect  the 
efficacy or safety of PEG-IFNs. In Alavian’s study, 
it  was  well  demonstrated  that  PEG-IFN  alfa-2a 
provides a higher virologic response than that of alfa-
2b. However, several factors that can interfere, such 
as  insulin  resistance,  racial  factors  (Asian  patients 
respond better to PEG-IFN, but there is a greater 
incidence  of  adverse  events  among  them),  gender 
effect (females respond better to therapy), in addition 
to some genetic factors, were not included in this 
analysis; moreover, the study would have been more 
informative if genotype 1 of HCV were analyzed 
separately, since this genotype represents the most 
resistant type of HCV infection. 
A  higher  prevalence  of  neutropenia  among 
patients treating with PEG-IFN alfa-2a was another 
interesting  finding  of  the  previously  mentioned 
meta-analysis.  Here  we  raise  a  question  about 
the  logic  behind  the  disparities  found:  Can  these 
observations be explained by a dose-response effect? 
McHutchison et al. (4) in their study found that a 
higher dosage of PEG-IFN alfa-2b is associated with 
a higher percentage in sustained virologic response 
(SVR), while a lower dosage was associated with a 
substantial  decrease  in  neutropenia  and  anemia. 
According to these findings, we might be able to 
simply  conclude  that  administration  of  a  higher 
dosage of PEG-IFN alfa-2b may result in a higher 
SVR rate as well as neutropenia, comparable to that 
of PEG-IFN alfa-2a.
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McHutchison et al. (4), whose data comprise over 
40% of the whole population in this meta-analysis, 
found that the relapse rate was substantially lower for 
PEG-IFN alfa-2b than for alfa-2a; another interesting 
observation of their study was that a lower dosage of 
PEG-IFN alfa-2b was associated with a lower relapse 
rate. The relapse rate was an important issue that was 
inevitably not considered in this study and needs to 
be addressed in future studies. 
Virologic response, although an important marker 
of  a  disease’s  progression  and  even  of  histological 
condition,  is  not  exactly  what  we  are  concerned 
about; long-term prognosis such as improvement in 
survival as well as a decrease in transplantation rate 
is what preoccupies us, and we need to confirm the 
efficacy of using both of these two agents in clinical 
practice. There is no evidence that virologic response 
would lead to a better outcome; on the other hand, 
unfortunately, there is a shortage of data on these 
hard  end  points  in  the  literature.  We  therefore 
recommend that this issue be urgently addressed in 
future studies.
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